whilst a positive scan could suggest the possibility of herpes simplex encephalitis, the final neuroradiological diagnosis rests on a high quality carotid angiogram, preferably done on a serial changer and from which subtraction films should be made.
Since then 3 suspected cases have been disproved by brain scanning and angiography; 6 patients have been diagnosed preoperatively by scanning and carotid angiography with subtraction studies, and have subsequently been proved to have herpes simplex. The symptoms of 5 patients had been present for 5-7 days and in one case the length of history was unknown. All the capillary phase changes we described for herpes simplex encephalitis were present in all 6 cases; when subtraction was used the hypervascularity could be subdivided into a blush and a venous plethora, both present in the 5 cases seen between five and seven days. All the cases also showed angiographic evidence of multiple site involvement but only 4 of them had midline shift and a temporal mass. The importance of correlation with the brain scan was emphasized by the fact that in the 5 cases in which satisfactory scans were performed temporal lesions were shown, although in one the angiogram did not show temporal space occupation. However, all the angiograms did show changes in the temporal lobes in the capillary phase. Displacement is absent because of balancing lesions in the other hemisphere.
We have now performed brain scans with 99Tcm in 10 proven cases of herpes simplex encephalitis. All cases were positive and all had a temporal lesion; 5 showed extensive temporal lesions, 5 showed bitemporal lesions, 4 showed wedge-like temporal lesions and in 8 there,were multiple uptakes. All patients had at least a fiveday history so we would expect the scan to be positive as the lesion is basically due to infarction.
We have come a long way since Amin (1972) thought that the neuroradiological features of herpes simplex encephalitis were nonspecific. We can now diagnose it with accuracy and recently we correctly suggested a diagnosis of herpes encephalitis in a case clinically diagnosed as cerebral tumour. In another patient we made a confident diagnosis of herpes encephalitis after scanning and angiography. A biopsy was taken that night, but the virological confirmation took six days. If any treatment is to be worth while one cannot always afford to wait for the virological proof, so high-quality neuroradiology is of great importance. Current Ideas and Treatment Plans for the Future Clinical studies of acute necrotizing encephalitis due to the herpes simplex virus have led to the conclusion that the disorder presents a double threat to the patient. First there is the threat of diffuse brain cellular death due to the rapid replication of the virus, and secondly there is the effect of a sudden and often localized increase in intracranial pressure. These processes may operate incdependently or in conjunction to produce the extraordinarily variable but very gloomy clinical picture with which we are now familiar.
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In a number of cases the presentation may be dramatically surgical, suggesting a rapidly developing abscess-like process, principally affecting the temporal lobes. Angiographic studies in such cases may reinforce the impression of a space-occupying lesion with displacement of cerebral vessels, somewhat unusual venous and anterior vascular circulation, but no sign of real tumour circulation. Adams & Jennett (1967) and Cope & Howieson (1967) described such cases and, as a direct consequence, the idea of surgical decompression emerged as one method of emergency treatment.
As a corollary of this surgical attempt at decompression other attempts were made to relieve pressure by medical means. Hypertonic solutions of urea or of mannitol were used, sometimes together with surgery; later, steroid preparations were brought into use. Many workers in virology, however, think that steroids used alone may exert an adverse effect on the viral infections, by facilitating replication of the viruses.
During the 1960s a number of compounds belonging to the pyrimidine group were found to exert an antiviral effect in vitro, seemingly by inhibiting DNA. Two of these pyrimidine analogues, idoxuridine and cytarabine, were employed in yarious clinical trials with varying results. Rappel (1973) analysed the results of a large number of cases of herpes simplex encephalitis (HSE) and concluded that the worst results were in cases which had no treatment: 205 deaths among 268 untreated cases. Among 101 cases treated in one way or another 49 patients survived. The treatment included surgery, steroids, and various combinations of idoxuridine and cytarabine. Firm conclusions about the best form of treatment could not be drawn from these figures; however, in a group of 8 cases treated with cytarabine only, there were 7 survivors. Similar modest successes were reported by other workers, particularly the Oxford group (Working Party on Herpes Simplex Encephalitis 1975).
Cooperative Stuidy of HSE Therapy
Following a symposium held in Manchester in January 1972 (Postgraduate Medical Journal 1973) , it was decided to establish a working party to set up a cooperative study of the value of antiviral drug therapy in cases of HSE. The group decided that the most satisfactory trial would not be one of' an antiviral agent alone, since in every case the patient would still be exposed to the dangers of cerebral cedema. The plan, therefore, is to carry out a double-blind trial in which the results using dexamethasone will be compared with those in which dexamethasone is accompanied either by cytarabine or by a placebo. The decision not to use idoxuridine has been more than justified by the recently published results of the Boston Interhospital Virus Study Group (1975) , whose study was concluded prematurely because of the unacceptable myelosuppression which became apparent and because of the failure of idoxuridine to prevent death; steroid therapy, however, was not used.
The absolute criteria for the admission to the British study, which will, we hope, embrace most of the neurological centres in Great Britain and also some on the Continent, will be establishment of the diagnosis by positive identification of the virus in brain biopsy material. Our experience and that of others is that brain biopsy has not produced any adverse effects on the disease, though Dr L S Illis (personal communication) thought that this procedure might have contributed to the decline of one of his patients.
Although it is possible to establish the virological diagnosis very rapidly we would emphasize that, if the other clinical criteria point strongly to the diagnosis of HSE, therapy need not be withheld until absolute confirmation is obtained. Our proposal is that, once biopsy has been performed, treatment should be given immediately; patients will then be removed from the study if absolute diagnostic confirmation is not made within five days of their provisional admission to trial. In this way we hope that the potentially conflicting demands of therapeutic humanity and the scientific results of treatment will both be satisfied.
Treatment Regimes
Each patient admitted to the study will receive: (1) Dexamethasone: (a) In children up to 10 kg body weight, a minimum dosage of 1 mg/kg load, followed by 2 mg every 6 hours for 8 doses, followed by 2 mg every 12 hours for 4 doses. (b) In children over 10 kg body weight, and for an average adult of up to 70 kg body weight, a minimum dosage of 10 mg/kg load, followed by 4 mg every 6 hours for 8 doses, followed by 4 mg every 12 hours for 4 doses. (c) For patients over 70 kg body weight, doses increased pro rata. In all cases the administration of dexamethasone may be continued or increased at the discretion of the clirPlcian.
(2) Either (a) cytosine arabinoside, 10 mg/kg body weight daily for five days, by a single bolus intravenous injection every 24 hours; or (b) placebo (perhaps mannitol solution), 0.5 ml/kg body weight daily for five days, by a single bolus intravenous injection every 24 hours; this very small dose of mannitol will have no therapeutic (decompressive) effect. Each vial will contain 100 mg cytosine arabinoside, or equivalent amount of dummy product.
(3) Other supportive drugs at the discretion of the clinician concerned (e.g. antibiotics, diuretics).
The problems of haematological adverse effects need very serious consideration. In Oxford 7 cases, in Manchester I 1, and in Brussels 5, have been treated with high doses of cytarabine. There is usually a drop in platelets and in reticulocytes with a more marked decline in the white cell count. The maximum suppression occurs in the second week and is followed by a rebound and spontaneous return to normal. One Manchester case and one Brussels case developed a severe fall in platelets but both recovered well following a single infusion of platelets (Working Party on Herpes Simplex Encephalitis 1975).
In the interests of the patients it is felt that blood counts should be monitored by the consultant who, in a hoematological emergency, will take the appropriate action.
